Identification of Phthalates in Medications and Dietary Supplement Formulations in the United States and Canada

DSpace/Manakin Repository

Identification of Phthalates in Medications and Dietary Supplement Formulations in the United States and Canada

Citable link to this page

 

 
Title: Identification of Phthalates in Medications and Dietary Supplement Formulations in the United States and Canada
Author: Kelley, Katherine E.; Hernández-Díaz, Sonia; Chaplin, Erica L.; Hauser, Russ B.; Mitchell, Allen Avrom

Note: Order does not necessarily reflect citation order of authors.

Citation: Kelley, Katherine E., Sonia Hernández-Díaz, Erica L. Chaplin, Russ Hauser, and Allen A. Mitchell. 2011. Identification of phthalates in medications and dietary supplement formulations in the United States and Canada. Environmental Health Perspectives 120(3): 379-384.
Full Text & Related Files:
Abstract: Background: In animal studies, some :ortho-phthalates, including di(2-ethylhexyl) phthalate (DEHP) and di-n-butyl phthalate (DBP), have been shown to be reproductive and developmental toxicants. Human studies show widespread population exposure to background levels of phthalates. Limited evidence suggests that particularly high exposure levels may result from orally ingested medicinal products containing phthalates as excipients (inactive ingredients). Objective: In this study we aimed to identify and describe the scope of prescription (RX) and nonprescription (over-the-counter; OTC) medicinal products and dietary supplements marketed in the United States and Canada since 1995 that include phthalates as excipients.: Methods: We used lists of modified-release drug products to identify potential drug products. Inclusion of phthalates was verified using available electronic databases, print references, published package inserts, product packages, and direct communication from manufacturers. Additional products were identified using Internet searches utilizing keywords for phthalates. Results: Based on labeling information, 6 RX drug products included DBP as an excipient, and 45 specified the use of diethyl phthalate (DEP). Phthalate polymers with no known toxicity—hypromellose phthalate (HMP), cellulose acetate phthalate (CAP), and polyvinyl acetate phthalate (PVAP)—were included in 75 RX products. Three OTC drug and dietary supplement products listed DBP, 64 listed DEP, and > 90 indicated inclusion of polymers.: Conclusions: Numerous RX and OTC drug products and supplements from a wide range of therapeutic categories may use DBP or DEP as excipients in oral dosage forms. The potential effects of human exposure to these phthalates through medications are unknown and warrant further investigation.
Published Version: doi:10.1289/ehp.1103998
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3295354/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:8620716
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters